Privium Fund Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Privium Fund Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,004	Closed	-$1.27K	–	167
2022 Q4	$1.27K	Hold	28,004	–	–	﹤0.01%	136
2022 Q3	$1K	Hold	28,004	–	–	﹤0.01%	208
2022 Q2	$3K	Hold	28,004	–	–	﹤0.01%	220
2022 Q1	$7K	Hold	28,004	–	–	﹤0.01%	251
2021 Q4	$17K	Buy	+28,004	New	+$19.4K	﹤0.01%	223

Privium Fund Management's BIOTW Position: Q1 2023 in Review

Privium Fund Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 28,004 shares — an estimated $1.27K sold.

Privium Fund Management first reported a position in BIOTW in Q4 2021 and held it in 5 quarters. The position peaked at $17K in Q4 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Privium Fund Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Privium Fund Management sold 28,004 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $1.27K.
Privium Fund Management first reported a position in Biotech Acquisition Company Warrant in Q4 2021 and held it in 5 quarters.
Privium Fund Management's Biotech Acquisition Company Warrant position peaked at $17K in Q4 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Privium Fund Management's 13F filing for Q1 2023, filed 3 May 2023.